New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis

Study Purpose:

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Our project aims to find new biomarkers in MRI at three levels: cerebral, medullary and muscular. These markers could allow an earlier diagnosis of the disease by showing more specific lesions of ALS and to quantify these lesions to measure the progression of the disease. This study will use advanced Magnetic Resonance Imaging (MRI) techniques High field (3T) and very high field (7T) MRI. Results from neurological and electrophysiological tests will be compared to the MRI. Subjects will be recruited from ALS center of Marseille, France. MRI will be done on ALS patients at baseline, at 3 month and at 6 month intervals.

Study Status:

Recruiting

Disease:

Amyotrophic Lateral Sclerosis

Study Type:

Interventional

Type of Intervention:

N/A

Intervention Name:

Muscular MRI, Electrophysiological exam, Brain MRI, Spinal cord MRI

Placebo:

Phase:

N/A

Study Chair(s)/Principal Investigator(s):

Emilie Garrido Pradalié, Direction Recherche Santé APHM

Clinicaltrials.gov ID:

NCT04691011

Neals Affiliated?

No

Coordinating Center Contact Information

Study Sponsor:

Assistance Publique Hopitaux De Marseille

Estimated Enrollment:

160

Estimated Study Start Date:

06 / 16 / 2021

Estimated Study Completion Date:

12 / 31 / 2026

Posting Last Modified Date:

04 / 25 / 2023

Date Study Added to neals.org:

12 / 31 / 2020